Intellectual Property Rights and Vaccines.

Biotechnology Commercialization Infringement Intellectual property Legal Patents Vaccines

Journal

Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969

Informations de publication

Date de publication:
2022
Historique:
entrez: 17 12 2021
pubmed: 18 12 2021
medline: 12 1 2022
Statut: ppublish

Résumé

Over the past 20 years, there has been steady, year-on-year growth in the number of granted vaccine-related patents. It is therefore important that those involved in vaccine research should be aware of both the risks and opportunities that patents create. The aim of this chapter is to offer a brief introduction to how, and when, patent rights might become available to vaccine developers and to explain the potential risk of infringement of third-party patent rights and the potential consequences.This chapter begins with a brief introduction to the patent application process and the international patent systems. The advantages and drawbacks of patent protection are discussed, followed by an overview of patent infringement and the various legal safe-harbors that may be available for certain research activities. Other features of the patent system which may be of particular relevance in the vaccines context are also discussed, such as compulsory licensing, sovereign states' rights to use patented inventions and voluntary technology sharing agreements. The chapter concludes with a discussion of the SARS-CoV-2 (COVID-19) pandemic and recent developments in the field of vaccine patents that have arisen as part of the international response.

Identifiants

pubmed: 34918265
doi: 10.1007/978-1-0716-1892-9_28
doi:

Substances chimiques

Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

505-518

Informations de copyright

© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Jacob, R. COVID-19 and IP (2020) World Intellectual Property Review (published online 25 September 2020, last accessed 24 September 2021)
Chiron v Evans Medical [1997] EWHC 359
Biogen v Medeva [1996] UKHL 18
GSK v Wyeth [2016] EWHC 1045
Merck v Wyeth [2020] EWHC 2636
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (last accessed 24 September 2021)
https://www.who.int/initiatives/covid-19-technology-access-pool (last accessed 24 September 2021)
https://innovation.ox.ac.uk/technologies-available/technology-licensing/expedited-access-covid-19-related-ip/ (last accessed 24 September 2021)
https://investors.modernatx.com/news-releases/news-release-details/statement-moderna-intellectual-property-matters-during-covid-19 (last accessed 24 September 2021)
https://clinicaltrials.gov/ct2/show/NCT05001373 (last accessed 24 September 2021)

Auteurs

Penny Gilbert (P)

Powell Gilbert LLP, London, UK. penny.gilbert@powellgilbert.com.

Richard Fawcett (R)

Powell Gilbert LLP, London, UK.

Joel Coles (J)

Powell Gilbert LLP, London, UK.

William Hillson (W)

Powell Gilbert LLP, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH